Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Emibetuzumab + Erlotinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Emibetuzumab||LY2875358||MET Antibody 16 MET Inhibitor 51||Emibetuzumab (LY2875358) is MET-targeted antibody, which inhibits binding of the MET ligand HGF and promotes internalization and downregulation of MET, resulting in decreased HGF-dependent and HGF-independent signaling and potentially leading to decreased growth of MET-expressing tumors (PMID: 27803065, PMID: 25231402, PMID: 31622732).|
|Erlotinib||Tarceva||CP358774||EGFR Inhibitor (Pan) 47 EGFR Inhibitor 1st gen 3||Tarceva (erlotinib) is a first-generation EGFR inhibitor, which is FDA approved for non-small cell lung carcinoma patients with EGFR exon 19 deletions and/or EGFR L858R and in combination with gemcitabine for patients with advanced pancreatic cancer (FDA.gov; PMID: 25302162).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||Emibetuzumab + Erlotinib||Phase II||Actionable||In a Phase II trial, the combination of Tarceva (erlotinib) and Emibetuzumab (LY2875358) compared to Tarceva (erlotinib) alone did not result in a significantly different median progression-free survival (9.3mo vs 9.5mo, respectively) and median overall survival (34.3mo vs 25.4mo, respectively) in patients with non-small cell lung cancer (PMID: 31622732).||31622732|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01900652||Phase II||Emibetuzumab + Erlotinib Emibetuzumab||A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants||Completed|
|NCT01287546||Phase I||Emibetuzumab + Erlotinib Emibetuzumab + Trametinib Emibetuzumab||A Study of LY2875358 in Participants With Advanced Cancer||Completed|